Sangamo Therapeutics, Inc.

Sangamo Biosciences, Inc.

Chdi Foundation, Inc.

The General Hospital Corporation

H Steve Zhang

Edward J Rebar

Philip D Gregory

Jeffrey C Miller

Steven Froelich

Fyodor Urnov

Gregory J Cost

Andreas Reik

Jianbin Wang

Russell DeKelver

Anthony Conway

Bryan Zeitler

David Paschon

Ignacio Munoz-Sanjuan

Lei Zhang

Bradley T Hyman

Sarah DeVos

Susanne Wegmann

Seung Kwak

Annemarie Ledeboer

Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.

Methods and compositions for treating Huntington's Disease

The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.

Tau modulators and methods and compositions for delivery thereof

The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.

Zinc finger protein compositions for modulation of huntingtin (Htt)

Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.

Htt repressors and uses thereof

Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.

Methods and compositions for treating Huntington's disease

Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.

Methods and compositions for treating trinucleotide repeat disorders

HTT repressors and uses thereof

Disclosed herein are methods and compositions for diagnosing, treating or preventing Huntington's Disease.

Methods and compositions comprising a CRISPR/Cas nuclease that cleaves a BCL11A gene for the modification of the BCL11A gene and for modification of globin expression.

Methods and compositions for treatment of a genetic condition

Methods and compositions comprising a CRISPR/Cas nuclease that cleaves a T cell receptor (TCR) gene and/or human leukocyte (HLA) gene, the nuclease comprising a cleavage domain and a single guide RNA that binds to a target site in the TCR and/or HLA gene.

Methods and compositions comprising a fusion protein comprising a Cas protein and a functional domain in association with a single guide RNA targeted to an endogenous gene for genetic alteration of cells are provided.

Growing community of inventors

Richmond, CA, United States of America

H Steve Zhang